webinar register page

Webinar banner
BIOBETTERS ACADEMY - Clinical experience with biobetters in IBD
Biosimilars are increasingly used to treat patients with IMIDs. Biobetters have changed the way oncology patients are treated. Biobetters may be associated with improvements in clinical outcomes and drug pharmacology. The first anti-TNF biobetter was recently approved for IBD. What is a biobetter? What is the current level of evidence in IBD? What are the indications of biobetters in IBD? These questions will be answered during this interactive webinar.

Intro 5’
Silvio Danese, Italy
Laurent Peyrin-Biroulet, France

Real-world evidence
for biobetters in IBD 15’
Shomron Ben-Horin, Israel

When to initiate? Clinical cases 15’
Gionata Fiorino, Italy

When to switch? Clinical cases 15’
Subrata Ghosh, Ireland

Q&A 10’

Dec 12, 2022 01:00 PM in Rome

* Required information